Literature DB >> 18199912

Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data.

V A Semenenko1, X A Li.   

Abstract

Knowledge of accurate parameter estimates is essential for incorporating normal tissue complication probability (NTCP) models into biologically based treatment planning. The purpose of this work is to derive parameter estimates for the Lyman-Kutcher-Burman (LKB) NTCP model using a combined analysis of multi-institutional toxicity data for the lung (radiation pneumonitis) and parotid gland (xerostomia). A series of published clinical datasets describing dose response for radiation pneumonitis (RP) and xerostomia were identified for this analysis. The data support the notion of large volume effect for the lung and parotid gland with the estimates of the n parameter being close to unity. Assuming that n = 1, the m and TD(50) parameters of the LKB model were estimated by the maximum likelihood method from plots of complication rate as a function of mean organ dose. Ninety five percent confidence intervals for parameter estimates were obtained by the profile likelihood method. If daily fractions other than 2 Gy had been used in a published report, mean organ doses were converted to 2 Gy/fraction-equivalent doses using the linear-quadratic (LQ) formula with alpha/beta = 3 Gy. The following parameter estimates were obtained for the endpoint of symptomatic RP when the lung is considered a paired organ: m = 0.41 (95% CI 0.38, 0.45) and TD(50) = 29.9 Gy (95% CI 28.2, 31.8). When RP incidence was evaluated as a function of dose to the ipsilateral lung rather than total lung, estimates were m = 0.35 (95% CI 0.29, 0.43) and TD(50) = 37.6 Gy (95% CI 34.6, 41.4). For xerostomia expressed as reduction in stimulated salivary flow below 25% within six months after radiotherapy, the following values were obtained: m = 0.53 (95% CI 0.45, 0.65) and TD(50) = 31.4 Gy (95% CI 29.1, 34.0). Although a large number of parameter estimates for different NTCP models and critical structures exist and continue to appear in the literature, it is hard to justify the use of any single parameter set obtained at a selected institution for the purposes of biologically based treatment planning. Our expectation is that the proposed model parameters based on cumulative experience at various institutions are more representative of the overall practice of radiation therapy than any single-institution data, and could be more readily incorporated into clinical use.

Entities:  

Mesh:

Year:  2008        PMID: 18199912     DOI: 10.1088/0031-9155/53/3/014

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  40 in total

1.  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.

Authors:  Francesco Giammarile; Lisa Bodei; Carlo Chiesa; Glenn Flux; Flavio Forrer; Françoise Kraeber-Bodere; Boudewijn Brans; Bieke Lambert; Mark Konijnenberg; Françoise Borson-Chazot; Jan Tennvall; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07       Impact factor: 9.236

2.  Dose-mass inverse optimization for minimally moving thoracic lesions.

Authors:  I B Mihaylov; E G Moros
Journal:  Phys Med Biol       Date:  2015-04-24       Impact factor: 3.609

3.  Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.

Authors:  Jeho Jeong; Jung Hun Oh; Jan-Jakob Sonke; Jose Belderbos; Jeffrey D Bradley; Andrew N Fontanella; Shyam S Rao; Joseph O Deasy
Journal:  Clin Cancer Res       Date:  2017-05-24       Impact factor: 12.531

Review 4.  Myths and realities of range uncertainty.

Authors:  Antony John Lomax
Journal:  Br J Radiol       Date:  2019-12-23       Impact factor: 3.039

5.  Non-coplanar VMAT combined with non-uniform dose prescription markedly reduces lung dose in breath-hold lung SBRT.

Authors:  Jens Fleckenstein; Judit Boda-Heggemann; Kerstin Siebenlist; Tanya Gudzheva; Natallia Prakofyeva; Frank Lohr; Frederik Wenz; Anna Simeonova-Chergou
Journal:  Strahlenther Onkol       Date:  2018-05-25       Impact factor: 3.621

6.  Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite.

Authors:  J Uzan; A E Nahum
Journal:  Br J Radiol       Date:  2012-03-28       Impact factor: 3.039

7.  Comparison of dose distribution for head and neck cancer patients with and without dose painting escalation during radiotherapy realized with tomotherapy unit.

Authors:  Malgorzata Skorska; Tomasz Piotrowski; Adam Ryczkowski
Journal:  Br J Radiol       Date:  2017-06-23       Impact factor: 3.039

8.  Quantitative assessment of irradiated lung volume and lung mass in breast cancer patients treated with tangential fields in combination with deep inspiration breath hold (DIBH).

Authors:  Brigitte Zurl; Heidi Stranzl; Peter Winkler; Karin Sigrid Kapp
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

9.  New approach in lung cancer radiotherapy offers better normal tissue sparing.

Authors:  Ivaylo B Mihaylov
Journal:  Radiother Oncol       Date:  2016-09-28       Impact factor: 6.280

10.  The relative biological effectiveness of carbon ion radiation therapy for early stage lung cancer.

Authors:  Jeho Jeong; Vicki T Taasti; Andrew Jackson; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2020-09-23       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.